EMG
BCLI

ETF Managers Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

ETF Managers Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,621
Closed -$424K – 661
2021
Q1 		$424K Buy
7,621
+1,361
+22% +$103K 0.01% 517
2020
Q4 		$435K Buy
6,260
+2,486
+66% +$339K 0.01% 404
2020
Q3 		$917K Buy
3,774
+293
+8% +$60K 0.03% 218
2020
Q2 		$579K Sell
3,481
-932
-21% -$100K 0.02% 247
2020
Q1 		$299K Buy
4,413
+392
+10% +$30.6K 0.01% 308
2019
Q4 		$259K Sell
4,021
-555
-12% -$32.2K 0.01% 462
2019
Q3 		$266K Buy
4,576
+1,746
+62% +$103K 0.01% 316
2019
Q2 		$169K Sell
2,830
-1,484
-34% -$86.4K 0.01% 493
2019
Q1 		$281K Sell
4,314
-139
-3% -$7.91K 0.01% 267
2018
Q4 		$237K Buy
4,453
+1,920
+76% +$94.6K 0.01% 281
2018
Q3 		$145K Buy
2,533
+596
+31% +$36K 0.01% 291
2018
Q2 		$102K Sell
1,937
-67
-3% -$3.94K 0.01% 226
2018
Q1 		$96K Buy
2,004
+334
+20% +$16.8K 0.01% 292
2017
Q4 		$91K Buy
1,670
+384
+30% +$23K 0.01% 248
2017
Q3 		$79K Buy
1,286
+79
+7% +$5.11K 0.01% 149
2017
Q2 		$75K Buy
+1,207
New +$74.4K 0.01% 207

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ETF Managers Group's BCLI Position: Q2 2021 in Review

ETF Managers Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 7,621 shares — an estimated $424K sold.

ETF Managers Group first reported a position in BCLI in Q2 2017 and held it in 16 quarters. The position peaked at $917K in Q3 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • ETF Managers Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • ETF Managers Group sold 7,621 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $424K.
  • ETF Managers Group first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2017 and held it in 16 quarters.
  • ETF Managers Group's BRAINSTORM CELL THERAPUTC position peaked at $917K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on ETF Managers Group's 13F filing for Q2 2021, filed 16 Aug 2021.